+86-28-82633987
Product name: Regaloside B
Synonym name:
Catalogue No.: BP4254
Cas No.: 114420-67-6
Formula: C20H26O11
Mol Weight: 442.417
Botanical Source: Lilii Bulbus
Type of Compound:
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
172.2100
-.4505
-.4526
8.7266
.4217
.1002
Low
34.8166
3.9734
Yes
No
No
No
No
No
0.3
Yes
Yes
Yes
Yes
Natural products, as an important source of drug discovery, hold a pivotal position in modern pharmacological research. Phenylpropane compounds have become one of the hot topics in natural product pharmacology research due to their diverse biological activities and unique chemical structures. Regaloside B is a phenylpropane compound isolated from the longiflorum plant of the Lilium genus, and has attracted attention in recent years for its remarkable anti-inflammatory and antioxidant activities. This compound not only regulates the expression of various inflammation-related factors but also shows potential value in physiological processes such as osteogenesis differentiation.
This paper will systematically review the chemical structure and physicochemical properties of Lilyoside B, plant origin, and extraction methods, focusing on its pharmacological activity and mechanism of action. It analyzes its pharmacokinetic characteristics combined with druggability parameters, and explores its clinical application prospects and future research directions, aiming to provide a theoretical foundation and research reference for the pharmacological development of this natural product.
Royal Liliside B has the molecular formula C_21H_26O_10, molecular weight 442.4170, and CAS number 114420-67-6. It has a typical phenylpropane glycoside-like structure, containing multiple hydroxyl and sugar groups, which imparts high polarity and water solubility. Physicochemical properties showed that the LogP value of king lilyside B was -0.4505, indicating strong hydrophilicity, water solubility of 8.7266, and a polarization surface area (TPSA) of 172.2100 Ų, indicating that its molecules have a high number of hydrogen bond donors and acceptors, facilitating stable binding with biological macromolecules.
Structurally, royal lilyside B contains a typical phenylpropane backbone, linked to glycoside residues, and multiple hydroxyl groups in its structure may be key sites of its biological activity. The polarity and spatial conformation of its molecular structure have significant effects on its bioavailability and targeting ability. Additionally, Wang Lihehe B does not have hERG channel inhibitory activity, while the Ames mutagenic test result was 0.3, indicating high safety and promising drug development potential.
King Liliside B is mainly isolated from the bulb of the long-flowered lily (Lilium longiflorum), a plant of the genus Lilium. Long-flowered lily, as a traditional Chinese medicinal herb and ornamental plant, contains abundant phenylpropane compounds and steroid saponins, possessing various pharmacological activities.
During extraction, alcohol extraction methods (such as methanol or ethanol) are commonly used to extract dried bulb powder, followed by separation and purification through liquid-liquid partitioning, silica gel column chromatography, and high-performance liquid chromatography (HPLC). Purified royal lilyside B can be structured by mass spectrometry (MS), nuclear magnetic resonance (NMR), and infrared spectroscopy (IR). In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, providing technical support for large-scale preparation.
King Liliside B exhibits significant anti-inflammatory effects. In vitro cell model studies have shown that king lilysin B can inhibit the expression of inflammatory mediators, including vascular cell adhesion molecule 1 (VCAM-1), induced nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2). The downregulation of these molecules effectively blocks the transmission of inflammatory signals, reducing cellular inflammatory responses.
Additionally, royal lily glycoside B significantly reduces the p-p65/p65 ratio in the NF-κB signaling pathway, inhibits activation of nuclear factor κB, and further blocks the transcription of inflammatory factors. It inhibits the mRNA expression of chemokines (such as CXCL9, CXCL10, IL8) and the immunoregulatory factor IDO, indicating its potential function in regulating the immune microenvironment and recruiting inflammatory cells.
As a natural phenylpropane compound, Wang Lihehe-Glycoside B has excellent antioxidant properties. By activating the nuclear factor E2-related factor-2 (Nrf2/NFE2L2) signaling pathway, it induces the expression of downstream antioxidant enzymes such as superoxide dismutase (SOD1, SOD2), catalase (CAT), glutathione peroxidase (GPX1), and heme oxygenase-1 (HMOX1), enhancing cellular antioxidant defenses and reducing oxidative stress damage.
In addition, royal urethraside B also regulates matrix metalloproteinases (MMP1, MMP3), helping to maintain the homeostasis of the extracellular matrix and prevent tissue damage caused by oxidative stress.
In recent years, king lily glycoside B has shown a positive effect in osteogenic differentiation research. By regulating the expression of genes related to bone formation and promoting the differentiation of bone marrow mesenchymal stem cells into osteoblasts, King Liliside B is expected to become a potential therapeutic agent for bone metabolic diseases such as osteoporosis. Its specific mechanism involves regulating the inflammatory microenvironment and redox status, providing favorable conditions for bone tissue repair.
The pharmacological effects of king heliside B mainly regulate inflammatory and oxidative stress-related signaling pathways. Its core mechanisms include:
NF-κB signaling pathway inhibition
King Liliside B lowers the p-p65/p65 ratio, inhibits nuclear translocation of NF-κB, blocks transcription expression of inflammatory genes, reduces the production of inflammatory mediators such as VCAM-1, iNOS, and COX-2, and alleviates inflammatory responses.
Nrf2-mediated antioxidant activation is also induced
By activating the Nrf2 transcription factor, royal lilyside B promotes the expression of downstream antioxidant enzymes (SOD1, SOD2, CAT, GPX1, HMOX1), enhancing the cells' ability to scavenge reactive oxygen species (ROS) and protecting them from oxidative damage.
Downregulation of chemokine and immune regulatory factor expression
It inhibits the mRNA expression of CXCL9, CXCL10, IL8, and IDO, regulates the recruitment and activation of immune cells, and alleviates chronic inflammatory states.
Matrix metalloproteinase regulation
By regulating the expression of MMP1 and MMP3, royal lilyside B helps maintain the integrity of the extracellular matrix and prevents tissue damage caused by inflammation and oxidative stress.
Signals that promote osteogenic differentiation
It may promote the differentiation of bone marrow mesenchymal stem cells into osteoblasts by affecting bone morphogenetic protein (BMP) and related transcription factors, thereby facilitating bone tissue repair.
From the perspective of druggability parameters, King Lily Glycoside B has the following characteristics:
Currently, pharmacokinetic data on king lily glycoside B are limited. It is speculated that its hydrophilicity and large polarized surface area may limit oral absorption, and its in vivo half-life and metabolic pathways require further study. In the future, structural modification or nanocarrier delivery methods are expected to improve its pharmacokinetic properties.
Based on the multi-target anti-inflammatory and antioxidant activity of royal lily glycoside B, its application potential is significant in various inflammation-related diseases. Especially in chronic inflammation, immune regulation, and bone metabolic diseases (such as osteoporosis and rheumatoid arthritis), Wang Lihehexio B shows promising application prospects.
Moreover, the low toxicity and safety of king lilysin B provide a foundation for its clinical translation. Future research may focus on:
Through multidisciplinary collaboration, King Lilyside B is expected to become a novel natural drug or lead compound, advancing the pharmacology of natural products.
King Lilyoside B, a phenylpropane natural product derived from Longhua Lily, demonstrates broad prospects for pharmacological research and clinical application due to its remarkable anti-inflammatory, antioxidant, and osteogenic differentiation promotion activities. Its mechanism of action involves key signaling pathways such as NF-κB and Nrf2, regulating the expression of various inflammatory factors and antioxidant enzymes, characterized by multi-target coordinated regulation.
Although pharmacokinetics and clinical research on king baiheside B are still in the early stages, its favorable safety and druggability parameters lay a solid foundation for subsequent development. In the future, through in-depth mechanistic research, structural optimization, and preclinical validation, Wang Liliuside B is expected to become an important candidate molecule in the field of natural product drug development, providing new ideas and strategies for the treatment of inflammatory and bone metabolic diseases.
Shenshuai
Wenjing
Hedandan
